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1 Both authors contributed equally to this study.VapB has been shown to regulate calcium homeostasis in amyotrophic lateral sclerosis. Calcium sig-
naling is also important in metabolic bone diseases, but the role of VapB in the generation of osteo-
clasts for bone resorption during osteoclastogenesis is not known. Therefore, we investigated the
role of VapB in RANKL-induced osteoclast differentiation. Interestingly, VapB is induced during
osteoclastogenesis, and regulates osteoclast differentiation by modulating NFATc1. The results also
suggest that VapB regulates osteoclastogenesis via PLCc2-Ca2+-NFAT signaling. The involvement of
PLCc2-Ca2+-NFAT signaling in VapB-regulated osteoclastogenesis was conﬁrmed by a pharmacolog-
ical study. Taken together, the results indicate that VapB positively regulates RANKL-mediated
osteoclastogenesis via PLCc2-Ca2+-NFAT signaling.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Osteoclasts are large multinucleated cells responsible for bone
degradation [1]. These cells are essential for skeletal development
and bone remodeling throughout life. Increased osteoclast number
and activity induces bone resorption, which can lead to osteoporo-
sis, periodontal disease, and rheumatoid arthritis [2,3]. To better
understand the mechanisms underlying osteoclast-mediated dis-
eases and to design relevant therapies, unveiling the regulatory
molecules that are closely associated with osteoclast differentia-
tion is necessary.
The RANKL-RANK signal also activates Ca2+ signaling through
the activation of phospholipase Cc (PLCc). Activated PLCc hydro-
lyzes phosphatidyl inositol 4,5-biphosphate (PIP2) to inositol-
1,4,5-triphosphate (IP3), which increases intracellular Ca2+. The in-
creased calcium level further stimulates the activation of NFATc1,chemical Societies. Published by E
f Anatomy, School of Medi-
n, Jeonbuk 570-749, Republic
Internal Medicine, Division of
dicine, 344-2 Sinyong-dong,
3 855 2025 (M.S. Lee).
s@wku.ac.kr, ckhlms@wonkwhich is induced by its auto-ampliﬁcatory property [4]. Ca2+ is a
ubiquitous intracellular messenger that mediates a variety of cellu-
lar functions, including cell proliferation, differentiation, and pro-
grammed cell death. In the case of osteoclastogenesis, Ca2+ plays
an important role in the sequential activation of calcineurin and
NFATc1 [5]. Recently, the tyrosine kinases Btk and Tec have been
shown to be involved in the activation of PLCc by linking RANK
and immunoreceptor tyrosine-based activation motif signals
[6,7]. However, the PLCc signal stimulated by RANKL to generate
Ca2+ oscillations and the mechanism underlying this oscillation is
not well known.
Vesicle-associated membrane protein-associated protein B/C
(VapB) is an established regulator of vesicle trafﬁcking [8]. Nisim-
ura et al. [9] identiﬁed a point mutation (P56S) of VapB in a large
Brazilian family with autosomal dominant motor neuron disease
with variable clinical courses. VapB is directly associated with typ-
ical amyotrophic lateral sclerosis (ALS), atypical ALS, and late-onset
spinal muscular atrophy [8,9]. These disorders are characterized by
selective motor neuron loss. Recently, Langou et al. [10] reported
that VapB selectively triggers motor neuron death through homeo-
static regulation of calcium. Though the role of VapB in ALS has
been extensively studied, the functional involvement of VapB in
normal biological events, such as osteoclastogenesis, has not been
well studied. Therefore, we investigated the possible involvement
of VapB in osteoclast differentiation.lsevier B.V. All rights reserved.
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2.1. Reagents and antibodies
Penicillin, streptomycin, a-MEM, and fetal bovine serum were
purchased from Invitrogen Life Technologies. Human soluble
RANKL and M-CSF were obtained from PeproTech. Antibodies
against NFATc1 and PLCc2 were purchased from Santa Cruz Bio-
technology. All others antibodies were obtained from Cell Signaling
Technology. Antibody against VapB was purchased from Abcam.
Anti-actin antibody was obtained from Sigma-Aldrich. Ionomycin
and BAPTA were purchased from Calbiochem and dissolved in
DMSO (Sigma-Aldrich). CsA was purchased from Sigma-Aldrich
and dissolved in ethanol. Synthetic calcium phosphate-coated
plates were purchased from Cosmo Bio Co., Ltd.
2.2. Osteoclast cell culture and co-culture
Bone marrow-derived macrophages (BMMs) were generated
as described previously [11]. To differentiate osteoclasts from
BMMs, the BMMs were cultured for 4–5 days with M-CSF
(30 ng/ml) and RANKL (100 ng/ml). To generate osteoclasts from
the co-culture of primary osteoblasts and bone marrow cells,
primary osteoblasts from newborn ICR mouse calvariae were
prepared by sequential digestion with 0.2% collagenase. These
cells were cultured to conﬂuence in a-MEM containing 10%
FBS and antibiotics. In brief, BMMs and primary osteoblasts
were co-cultured in a-MEM complete medium with
1.25(OH)2D3 and PGE2 in 48-well plates. The medium was chan-
ged every 3 days. After 6 days in culture, the cells were ﬁxed in
10% formalin for 5 min, permeabilized with 0.1% Triton X-100,
and stained for tartrate-resistant acid phosphatase (TRAP) using
kit 387-A (Sigma, St Louis, MO) according to the manufacturer’s
instructions.
2.3. Western blotting
Cultured cells were washed with ice-cold phosphate-buffered
saline (PBS) and lysed in lysis buffer (50 mM Tris–HCl, 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM sodium ﬂuoride,
1 mM sodium vanadate, and 1% deoxycholate) containing prote-
ase inhibitors. To prepare cytosolic and nuclear extracts, cultured
cells were fractionated using Nuclear and Cytoplasmic Extraction
Reagents (Thermo scientiﬁc). The cell lysates were boiled in SDS
sample buffer for 5 min, subjected to 10% or 15% SDS–PAGE,
and transferred to a polyvinylidene diﬂuoride membrane (Milli-
pore). The membrane was probed with the indicated primary
antibody, washed three times for 30 min, incubated with second-
ary antibody conjugated to horseradish peroxidase (HRP) for 2 h,
and washed three times for 30 min. Protein was visualized using
ECL and X-ray ﬁlm.
2.4. Constructs and retrovirus preparation
The VapB gene was prepared by reverse transcriptase-polymer-
ase chain reaction (RT-PCR) using RNA from BMMs. The primer se-
quences were as follows: VapB forward (BamHI), 50-GCTAGGATCCA
TGGCGAAGGTGGAACAGGT-30; VapB reverse (NotI), 50-GCTAGCGGC
CGCCAAGGCAATCTTCCCTATAA -30. VapB was cloned into the retro-
viral vector pMX-puro (Cell Biolabs). RNAi oligonucleotides were
sh-VapB forward (50-GATCCCCGGTGATGGAAGAGTGCAGGTTCAAG
AGACCTGCACTCTTCCATCACCTTTTTC-30) and reverse (50-TCGAGA
AAAAGGTGATGGAAGAGTGCAGGTCTCTTGAACCTGCACTCTTCCATC
ACC-30). The oligonucleotides were cloned into the retroviral small
interference RNA (siRNA) vector pSuper-retro-Puro (OligoEngine).Retroviral packaging was performed by transfecting the plasmids
into Plat-E cells using Lipofectamine 2000 (Invitrogen). Viral
supernatant was collected from the culture media 48 h after trans-
fection. BMMs were incubated with viral supernatant in the pres-
ence of polybrene (8 lg/ml). After infection, BMMs were cultured
overnight, detached using StemPro Accutase Cell Dissociation
Reagent (Invitrogen), and further cultured with M-CSF (30 ng/ml)
and puromycin (2 lg/ml) for 2 days. Puromycin-resistant BMMs
were induced to differentiate in the presence of M-CSF (30 ng/
ml) and RANKL (100 ng/ml) for 4–5 days.2.5. RNA isolation and RT-PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) accord-
ing to the manufacturer’s recommended protocol. Reverse tran-
scription was performed with 1 lg of RNA using oligo(dT)
primers, dNTP, buffer, DTT, RNase inhibitor, and SuperScript II re-
verse transcriptase (Invitrogen). The cDNA was ampliﬁed using an
i-Star Taq premix PCR kit (Intron Bio). The primers used in the
PCR were as follows: VapB forward, 50-AGATTGCCTTGTAGGGGC
CG-30; VapB reverse, 50-GGAAGCCACGTGGGTAAGAA-30; TRAP for-
ward, 50-ACTTCCCCAGCCCTTACTAC-30; TRAP reverse, 50-TCAGCACA
TAGCCCACACCG-30; OSCAR forward, 50-GAACACCAGAGGCTATGAC
TGTTC-30; OSCAR reverse, 50-CCGTGGAGCTGAGGAAAAGGTTG-30;
cathepsin K forward, 50-AGGCGGCTATATGACCACTG-30; cathepsin
K reverse, 50-CCGAGCCAAGAGAGCATATC-30; GAPDH forward, 50-
ACCACAGTCCATGCCATCAC-30; GAPDH reverse, 50-TCCACCACCCTG
TTGCTGTA-30; NFATc1 forward, 50-CTTCAGCTGGAGGACACCCC-30;
NFATc1 reverse, 50-GGAAGACCAGCCTCACCCTG-30. PCR products
were electrophoresed on a 1% agarose gel stained with ethidium
bromide.2.6. Pit formation assay
Mature osteoclasts derived from retrovirus-transduced BMMs
(7  104 cells/well in 24-well plate) were cultured in a-MEM plus
10% FBS with RANKL (100 ng/ml) and M-CSF (30 ng/ml) on syn-
thetic carbonate apatite-coated plates. The medium was replaced
every 3 days. After multinucleated osteoclasts were observed at
4–5 days, cultured cells were washed with PBS and treated with
5% sodium hypochlorite for 5 min. After washing the plate with
PBS buffer and drying it, it was photographed under a light micro-
scope. Quantiﬁcation of resorbed areas was performed using the
Image Pro-plus program, version 4.0 (Media Cybernetics, MD).2.7. TRAP activity assay
To measure TRAP activity, multinucleated osteoclasts were
ﬁxed in 10% formalin for 5 min and permeabilized with 0.1% Triton
X-100 for 10 min. The osteoclasts were treated with TRAP buffer
(100 mM sodium acetate pH 5.0, 50 mM sodium tartrate) contain-
ing 3 mM P-nitrophenyl phosphate (Sigma-Aldrich) at 37 C for
5 min. Reaction mixtures in the wells were transferred into new
plates containing an equal volume of 0.5 N NaOH, and optical den-
sity (OD) values were determined at 405 nm.
2.8. Statistical analysis
All quantitative values are presented as mean ± SD. Each exper-
iment was performed three to ﬁve times, and results from one rep-
resentative experiment are shown. Statistical differences were
analyzed using Student’s t test. A value of p < 0.05 was considered
signiﬁcant.
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3.1. VapB expression is increased during RANKL-induced
osteoclastogenesis
To assess the possible involvement of VapB in osteoclastogene-
sis, we analyzed the expression of VapB during RANKL-induced dif-
ferentiation of primary mouse bone marrow-derived macrophages
(BMMs) into osteoclasts. When BMMs differentiated into osteo-
clasts upon treatment with RANKL in the presence of M-CSF, VapB
mRNA expression was time-dependently induced during osteo-
clast differentiation (Fig. 1A). RANKL-induced osteoclast differenti-
ation was conﬁrmed by evaluating markers of osteoclastogenesis,
including NFATc1 and its target molecules (TRAP, OSCAR, and
cathepsin K), and the mRNA expression of these genes was also
time-dependently induced by RANKL. The protein level of VapB
was also increased during osteoclastogenesis (Fig. 1B). These
results suggest that VapB could be associated with the process of
RANKL-mediated osteoclast differentiation.
3.2. Down-regulation of VapB inhibits RANKL-induced osteoclast
differentiation
To investigate the role of VapB in the regulation of osteoclast dif-
ferentiation, a retrovirus-based loss-of-function analysis was per-
formed. Before evaluating the functional role of VapB in
osteoclastogenesis, the efﬁciency of its knock-down was conﬁrmed
by RT-PCR and Western blotting; the mRNA and protein levels of
VapB were decreased in VapB-speciﬁc shRNA retrovirus-infected
BMMs when evaluated 2 days after infection. Moreover, VapB was
not induced in VapB-silenced BMMs, even in additional culture
with RANKL for 3 days (Fig. 2A). Additionally, the RANKL-induced
mRNA levels of NFATc1 and its target genes (TRAP, OSCAR, and
cathepsin K) were attenuated, and the RANKL-stimulated induction
of NFATc1 protein was strongly attenuated by VapB down-regula-Fig. 1. VapB expression increased during osteoclast differentiation. BMM cells were
induced to differentiate into osteoclasts with RANKL and M-CSF treatment. (A)
Semiquantitative RT-PCR showed a slight increase in VapB mRNA expression during
osteoclast differentiation. (B) Immunoblot analysis showed an increased VapB
protein level during osteoclastogenesis.tion, suggesting involvement of NFATc1 in the function of VapB in
osteoclastogenesis. When VapB-silenced BMMs were cultured for
5 days with various concentrations of RANKL, TRAP-positive multi-
nucleated osteoclasts were less formed compared to control (Fig. 2B
and C). TRAP activity was also decreased in osteoclasts generated
from VapB-silenced BMMs (Fig. 2C, bottom panel). When VapB-si-
lenced BMMs were co-cultured with primary calvarial osteoblasts
in the presence of VitD3 and PGE2, the number of TRAP-positive
multinucleated osteoclasts was signiﬁcantly reduced (Fig. 2D). In
addition, VapB down-regulation resulted in decreased bone resorp-
tion on hydroxyapatite-coated plates. This result could be due to a
defect in the maturation of the osteoclasts via down-regulation of
VapB (Fig. 2E). Taken together, these results suggest that down-reg-
ulation of VapB inhibits RANKL-induced osteoclastogenesis.
3.3. Over-expression of VapB enhances osteoclastogenesis via RANKL
Because VapB silencing was shown to act as a negative regula-
tor of osteoclast differentiation by decreasing NFATc1, we exam-
ined the effect of VapB over-expression in osteoclastogenesis
using a retrovirus-based gain-of-function model. The over-expres-
sion of VapB in BMMs infected with VapB retrovirus was conﬁrmed
by RT-PCR and Western blot (Fig. 3A). Additionally, the RANKL-
induced mRNA levels of NFATc1, TRAP, OSCAR, and cathepsin K,
and protein levels of NFATc1 were enhanced by VapB over-expres-
sion. When BMMs over-expressing VapB, the number of TRAP-po-
sitive osteoclasts were prominently higher than in control
experiments (Fig. 3B and C). TRAP activity in osteoclasts generated
from BMMs over-expressing VapB was also higher than in the con-
trol (Fig. 3C, bottom panel). In the co-culture system, to mimic
endogenous RANKL-induced osteoclastogenesis, the number of
TRAP-positive multinucleated osteoclasts was induced by VapB
over-expression (Fig. 3D). Furthermore, VapB induction substan-
tially enhanced the area of resorption pits (Fig. 3E). These results
suggest that VapB over-expression accelerates RANKL-induced
osteoclast differentiation.
3.4. VapB regulates osteoclast differentiation via activation of the
PLCc2-calcium-NFATc1 signaling axis
To gain insight into the mechanism by which VapB positively
regulates osteoclast differentiation with the induction of NFATc1
expression, we investigated the effect of VapB on the activity of
molecules that regulate RANK signaling. As MAP kinases are well
known to be involved in osteoclastogenesis [1], the effect of VapB
on the activation of MAP kinase was evaluated. RANKL induced the
activation of p38, ERK, and JNK, and the degradation of I-jB in both
VapB-silenced BMMs and BMMs over-expressing VapB, but the
levels were not different from control (Fig. 4A and B). However,
PLCc2 was inactivated in VapB-silenced BMMs (Fig. 4A) and acti-
vated in BMMs over-expressing VapB (Fig. 4B). In addition, VapB-
silenced BMMs showed decreased nuclear translocation of NFATc1
(Fig. 4C). In contrast, NFATc1 nuclear translocation was induced by
VapB over-expression and its induction was completely inhibited
by cyclosporine A (CsA) (Fig. 4D). PLCc activation evokes a Ca2+ sig-
nal, which is required for the activation and induction of NFATc1 in
osteoclast differentiation [4]. Considering our results showing that
NFATc1 is positively regulated by VapB expression, these results
suggest that NFATc1 might be the major effector molecule in the
regulation of VapB-mediated osteoclastogenesis.
Therefore, we evaluated the possible involvement of the Ca2+-
NFAT signaling axis in VapB-mediated osteoclastogenesis with
pharmacological activation and an inhibition study. As shown in
Fig. 4E and F, in VapB-silenced BMMs, the TRAP-positive
multinucleated osteoclasts were less formed upon RANKL treat-
ment. However, treatment with ionomycin (an ionophore to raise
Fig. 2. Down-regulation of VapB suppressed RANKL-induced osteoclast differentiation. (A) BMM cells were infected with retroviruses encoding VapB-speciﬁc shRNA (sh-
VapB) or pSuper-retro-puro (control) and selected with puromycin (2 lg/ml) for 2 days. Infected BMMs were cultured with RANKL (100 ng/ml) for the indicated days in the
presence of M-CSF (30 ng/ml) and the mRNA or protein expression analyzed by RT-PCR and Western blot, respectively. (B) Infected BMMs were cultured for 5 days in the
presence of RANKL (0, 25, 50, or 100 ng/ml) and M-CSF (30 ng/ml). Cells were ﬁxed in 3.7% formalin, permeabilized with 0.1% Triton X-100, and stained with TRAP solution.
Mature TRAP-positive multinucleated osteoclasts (MNCs) were photographed under a light microscope (magniﬁcation 100). (C) TRAP-positive MNCs (top panel), TRAP-
positive MNCs (nuclear number >3; middle panel), and TRAP activity (bottom panel) in osteoclasts generated from the control BMMs (black column) or VapB-silenced BMMs
(white column) were counted and measured. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 versus control. (D) Infected BMMs were co-cultured with primary osteoblasts for 6 days and then ﬁxed
and stained for TRAP (magniﬁcation 100). TRAP-positive MNCs were counted. ⁄⁄⁄P < 0.001 versus control. (E) Mature osteoclasts derived from infected BMMs were cultured
on carbonate apatite-coated plates for 5 days. Cells were removed and photographed under a light microscope. The bone resorption area was quantiﬁed using the Image Pro-
plus program, version 4.0. ⁄⁄⁄P < 0.001 versus control.
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duced formation of TRAP-positive multinucleated osteoclasts in
VapB-silencedBMMs. The slight enhancement caused by ionomycin
was also observed in control BMMs. In addition, a strong ionomycin-
mediated induction of NFATc1 protein expression was also
observed in VapB-silenced BMMs (Fig. 4G). These results suggest
that VapB silencing inhibits osteoclastogenesis by blocking the
PLCc2-Ca2+-NFAT signaling axis.
Conversely, we also evaluated the effect of BAPTA (a calcium-
speciﬁc chelator) on VapB-mediated osteoclastogenesis. Treatment
with BAPTA signiﬁcantly inhibited RANKL-induced osteoclasto-
genesis in both the control BMMs and BMMs over-expressing VapB
(Fig. 4H). The number of TRAP-positive multinucleated osteoclasts
generated by BMMs over-expressing VapB was completely reduced
by BAPTA (Fig. 4I). Furthermore, NFATc1 was induced by VapB
over-expression, but its induction was strongly inhibited by treat-
ment with BAPTA (Fig. 4J). Taken together, these results suggest
that over-expression of VapB promotes osteoclastogenesis by acti-
vating the PLCc2-Ca2+-NFAT signaling axis.
4. Discussion
The role of VapB in ALS has been extensively studied [8,9], but
the functional involvement of VapB in the process of normal bio-logical events, such as osteoclastogenesis, has not been well stud-
ied. Therefore, in this study, we investigated the possible
involvement of VapB in osteoclast differentiation. Interestingly,
VapB was induced during osteoclastogenesis and its functional
involvement in the process conﬁrmed by retrovirus-based loss-
of-function and gain-of-function analyses. VapB acts as a positive
regulator of RANKL-induced osteoclastogenesis.
The activation of NFATc1 requires assembly of the RANKL-
RANK-MAP kinases and PLCc-Ca2+ signaling. MAP kinase family
members selectively phosphorylate serine and/or threonine resi-
dues of protein substrates in response to extracellular stimuli
and transmit the stimuli from the cell surface to the nucleus. In
osteoclast precursors, RANKL triggers the activation of MAP
kinases that consequently induce the activation of transcription
factors, such as NF-jB, NFATc1, and activator protein-1 (AP-1)
[1]. Although a change in the activation of MAP kinases due to
VapB silencing or over-expression was not observed in this study,
we found a possible involvement of the PLCc-Ca2+-NFAT signaling
axis in VapB-mediated enhancement of osteoclastogenesis.
Two forms of PLCc are known, PLCc1 and 2; PLCc1 is widely
distributed, whereas the expression of PLCc2 is primarily limited
to cells of the hematopoietic lineage [12]. Both PLCc isoforms
require phosphorylation on speciﬁc tyrosine residues for catalytic
activity [13]. Interestingly, targeted deletion of PLCc2, but not
Fig. 3. Over-expression of VapB accelerated RANKL-induced osteoclastogenesis. (A) BMMs were transduced with retroviruses harboring VapB or pMX-IRES-PURO (control),
selected with puromycin (2 lg/ml) for 2 days, and cultured for 3 days in the presence of RANKL. The mRNA and protein levels were analyzed by RT-PCR and immunoblotting.
(B) Transduced BMMs were cultured for 4 days with M-CSF alone or M-CSF and increasing concentrations of RANKL as indicated. Cultured cells were ﬁxed and stained for
TRAP. (C) Numbers of TRAP-positive multinucleated cells were counted and TRAP activity measured. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 versus control. (D) Transduced BMMs were co-
cultured for 6 days with osteoblasts in the presence of 1.25(OH)2D3 and PGE2. Cultured cells were ﬁxed and stained for TRAP. TRAP-positive MNCs were counted. ⁄⁄⁄P < 0.001
versus control. (E) Transduced BMMs were cultured on carbonate apatite plates for 4 days. Cells were removed and photographed under a light microscope. The bone
resorption area was quantiﬁed using the Image Pro-plus program, version 4.0. ⁄⁄⁄P < 0.001 versus control.
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that PLCc2 is the critical isoform in the regulation of RANKL
-induced osteoclastogenesis [14]. In addition, mice harboring a tar-
geted deletion of PLCc2 exhibit decreased NFATc1 expression [14].
Considering our results that VapB stimulated RANKL-induced
osteoclastogenesis with PLCc2 activation and NFATc1 induction,
the PLCc2-NFATc1 signaling axis could be directly associated with
the VapB activity enhancing RANKL-induced osteoclastogenesis.
Furthermore, the RANKL-RANK signal activates Ca2+ signaling
via the phosphorylation of PLCc [4,5]. Additionally, Takayanagi
[1] reported that RANKL evokes Ca2+ oscillation and accelerates
Ca2+–dependent NFAT translocation. Nuclear translocated NFATc1
forms a complex with a transcription factor, such as NF-jB and/
or c-Fos, and activates the transcription of NFAT target genes.
Importantly, in this study, we found the reduction of NFATc1
nuclear localization by VapB down-regulation. Moreover, over-
expression of VapB induced NFATc1 nuclear localization, but its
induction was completely inhibited by CsA. In addition, the cal-
cium ionophore ionomycin activated RANKL-induced differentia-tion of cells into osteoclasts via the intracellular calcium
concentration, causes phosphorylation of NFATc1, and induces
expression of the protein [15]. However, the calcium chelator BAP-
TA inhibited RANKL-induced osteoclast differentiation by decreas-
ing calcium levels [16]. In this study, the inhibition of
osteoclastogenesis induced by silencing VapB was almost rescued
by ionomycin with NFATc1 induction, and VapB-mediated
enhancement of RANKL-induced osteoclastogenesis was strongly
inhibited by BAPTA with decreased NFATc1 expression. These
results suggest the involvement of Ca2+-NFAT signaling in the
VapB-mediated enhancement of osteoclastogenesis.
Furthermore, VapB has been reported to be associated with
endoplasmic reticulum (ER) stress and Unfolded Protein Response
(UPR) in ALS [17,18]. Recently, Wang et al. [19] reported that ER
stress can lead to osteoclast differentiation. ER stress results from
the accumulation of misfolded proteins which leads to the induc-
tion of the UPR. Also, Wang et al. [19] reported that ER stress in
osteoclast precursors was demonstrated by the ﬁndings that inhi-
bition of ER stress inhibited differentiation and known ER stress
Fig. 4. VapB regulates calcium signaling through PLCc2-mediated osteoclast differentiation. (A–B) BMM cells were infected with retroviruses encoding VapB-speciﬁc shRNA
(sh-VapB) or pSuper-retro-puro (control) and VapB or pMX-IRES-PURO (control), selected with puromycin (2 lg/ml) for 2 days, and cultured for 1 day in the presence of M-
CSF. Infected BMMs were serum starved for 12 h and stimulated with RANKL (100 ng/ml) for the indicated times. Cell lysates were subjected to Western blotting. (C–D)
Selected BMMs were cultured for 3 days with M-CSF alone or M-CSF plus RANKL in the absence or presence of CsA (2 lg/ml). Cytosolic and nuclear fractions were harvested
from cultured cells and Western blot analysis was performed. (E–F) Infected BMMs were treated daily with DMSO or ionomycin (10 nM) for 2 h in serum starved media
without M-CSF and RANKL, then washed two times with media before being stimulated with M-CSF (30 ng) and RANKL (100 ng/ml); the process was repeated for 4 days.
Cultured cells were ﬁxed and stained with TRAP solution. Mature TRAP-positive multinucleated osteoclasts (MNCs) were photographed under a light microscope
(magniﬁcation 100; E) and TRAP-positive MNCs counted (F). ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 versus control. (G) Infected BMMs were treated daily with DMSO or ionomycin (10 nM)
for 2 h in starved media, washed two times with media and stimulated with M-CSF (30 ng/ml) and RANKL (100 ng/ml). This process was repeated for 3 days, then Western
blotting analysis was performed. (H–I) Transduced BMMs were treated daily with DMSO or BAPTA (2 lM) for 2 h in starved media, washed two times with media, and
stimulated with M-CSF (30 ng/ml) and RANKL (100 ng/ml). Cultured cells were ﬁxed and stained with TRAP solution. TRAP-positive MNCs were photographed under a light
microscope (H) or TRAP-positive MNCs counted (I). ⁄P < 0.05, ⁄⁄⁄P < 0.001 versus control. (J) Transduced BMMs were treated daily with DMSO or BAPTA (2 lM) for 2 h in
starved media, washed two times with media, stimulated with M-CSF (30 ng/ml) and RANKL (100 ng/ml). The process was repeated for 3 days and Western blotting analysis
was performed.
268 S.-W. Choi et al. / FEBS Letters 586 (2012) 263–269inducers caused differentiation. The functional connection
between VapB, ER stress and osteoclast differentiation might be
elucidated in a further study.
In conclusion, VapB is induced during osteoclastogenesis and
positively regulates osteoclast differentiation by controlling the
activation of PLCc2-Ca2+-NFAT signaling. To the best of our knowl-
edge, this is the ﬁrst study showing the involvement of VapB in
osteoclastogenesis. Our results may provide a basis for exploring
the therapeutic potential of VapB silencing for metabolic bone dis-
eases, such as osteoporosis and rheumatoid arthritis.
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